Long-term effects of stimulants on neurocognitive performance of Taiwanese children with attention-deficit/hyperactivity disorder by Ching-Shu Tsai et al.
Tsai et al. BMC Psychiatry 2013, 13:330
http://www.biomedcentral.com/1471-244X/13/330RESEARCH ARTICLE Open AccessLong-term effects of stimulants on neurocognitive
performance of Taiwanese children with
attention-deficit/hyperactivity disorder
Ching-Shu Tsai1, Yu-Shu Huang2*, Chen-Long Wu3,4, Fang-Ming Hwang5, Kin-Bao Young6, Ming-Horng Tsai7
and Shih-Ming Chu7Abstract
Background: Attention-deficit/hyperactivity disorder (ADHD) is a common behavioral and neurocognitive disorder
in school-age children. Methylphenidate (MPH) is the most frequently prescribed CNS stimulant for ADHD. The
aim of this study is to evaluate the changes in intelligence quotient and domains of neurocognitive function after
long-term MPH treatment of Taiwanese children with ADHD.
Methods: The Wechsler Intelligence Scale (WISC-III) was administrated twice at an interval of at least one year for
all 171 subjects (6–12 years) and 47 age- and gender-matched children without ADHD. The ADHD-Rating scale and
Clinical Global Impression-Severity (CGI-S) were also used at the time of enrolment, and at 6 months and one year later.
Results: Taiwanese children with ADHD had lower Verbal IQ (VIQ) and Full IQ (FIQ) and performed poorly on several
subtests of the WISC-III, including Similarities, Vocabulary, and Coding, compared to healthy children without ADHD.
After one year of MPH treatment, significant decrements in all scores of the ADHD-Rating scale and CGI-S and
increments in several domains of the WISC-III, including FIQ, VIQ, PIQ, Perceptual Organization Index (POI), Picture
Completion, Picture Arrangement, Object Assembly, and Digit Span were observed. When the ADHD children under
MPH treatment were subdivided into two age groups (6–8 years and 9–12 years), significantly better performance in
some subtests and subscales of the WISC-III (such as Similarities, Comprehension, and Object assembly) was found in
the 6–8 years age group.
Conclusions: Long-term MPH treatment may improve the neurocognitive profiles of the ADHD children, as seen in
their performance in several subtests and in the IQ scores on the WISC-III. And this improvement had no correlation
with the decrement of ADHD symptoms. Starting stimulant treatment at as young an age as possible is advised due
to the greater benefits in the 6–8 years age group, as seen in this study. More research in this area is also needed to
confirm these results.
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Attention deficit hyperactivity (ADHD), one of the most
common behavioral and neurocognitive disorders [1], is
characterized by persistent over activity, inattention and
impulsivity. The American Psychiatric Association (APA,
1994) diagnostic guideline [Diagnostic and Statistical
Manual, version IV (DSM-IV)] classified ADHD into three* Correspondence: hu1109s@yahoo.com.tw
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reproduction in any medium, provided the orsubtypes: (a) inattentive, (b) hyperactive–impulsive and
(c) combined. According to the DSM-IV, text version
(DSM-IV-TR) diagnostic guidelines, the prevalence of
ADHD is estimated at 3–7% in school-age children [2,3].
Due to the nature of the populations sampled, diagnostic
criteria used, cultural differences, and methodological
limitations, the prevalence of ADHD in various cultures
varies. The prevalence is estimated to be about 8.4–11.7%
in Taiwan [4]; 2.4% in Australia [5]; and 4% in Japan [6].
The negative outcomes of ADHD include peer rejection,
low self-esteem, academic underachievement, and learning. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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executive dysfunction and a lower intellectual coefficient
were also found in ADHD children. Although the concept
of executive function is broad and variable, overall it is
used in reference to the higher brain process involved in
planning problem-solving and can be screened using
the Wechsler Intelligence Scale (WISC) [9]. From the
intellectual coefficient perspective, a meta-analytic review
by Frazier et al. reported that the ADHD groups performed
at an average of 9.15 points lower than the control
group in their Full Scale Intelligence Quotient (FSIQ),
assuming a theoretical standard deviation of 15 [10].
Methylphenidate (MPH), a kind of central nervous sys-
tem (CNS) stimulant, is the most frequently prescribed
medication for ADHD, and its clinical efficacy is well
established [11]. The effects of MPH on attention result
from a combination of noradrenergic and dopaminergic
mechanisms [12], which are assumed to ameliorate the
two principal problems of attention deficiency and impul-
sivity/hyperactivity in children with ADHD. Moreover,
scholars hypothesized that treating ADHD symptoms
via stimulant drugs not only decreased the negative impact
of ADHD, but possibly also benefited the neurocognitive
performances of children with ADHD [13]. A previous
meta-analysis by Kavale et al. found that stimulant
treatment for an average period of 18 weeks led to a mean
gain of about 6 to 7 points in FSIQ, and 6 points in both
the Verbal Intelligence Quotient (VIQ) and Performance
Intelligence Quotient (PIQ) [14]. Another meta-analysis
by Thurber and Walker [15] also demonstrated that
short-term stimulant drug effects could result in a
mean increase of 2.25 points in the FSIQ. Recent studies
that focus on intellectual outcomes after a long-term
treatment period have shown that long-term stimulant
treatment for at least one year could increase the
Intelligence Quotient (IQ) score in children with ADHD,
and that more improvement in IQ scores was found in the
group of those who could maintain a longer treatment
duration [16,17]. That is, the intellectual performance of
children with ADHD may be improved with long-term
CNS stimulant treatment, as well as short-term stimulant
treatment, but a bigger gain with long-term treatment
is suspected. In addition to the decreased severity of
core symptoms, avoidance of negative consequences
and improved neurocognitive performances of children
with ADHD, MPH has been shown to counteract the
detrimental effects of earlier-origin developmental insults
[18] and has age-dependent effects on prefrontal neurons
[19,20]. So it is also suspected that starting drug treatment
at an earlier age may have more benefits.
In Taiwan, a high prevalence rate of ADHD was noticed
about ten years ago [4], but there is still little research
comparing neurocognitive function between children
with ADHD and healthy children. And even though thepositive effect of CNS stimulants in ADHD treatment has
been reported in many studies, there are still few studies
examining the long-term effect of CNS stimulants on
neurocognitive function and in different age groups.
Therefore, in this study, we have several objectives as
below: 1) to better understand the neurocognitive
performance of ADHD children in Taiwan as measured
by the WISC-III and to further compare the results
with healthy controls; 2) to investigate the changes in
rating scale and IQ and the influences on the domains
of the WISC subtests after long-term MPH treatment
in Taiwanese children with ADHD; 3) to explore if
there is more benefit to long-term MPH treatment; and
4) to know if MPH treatment has a diverse effect on
neurocognitive profiles in different age groups.
Methods
Participants
We collected ADHD children from the outpatient clinics
of a medical center in northern Taiwan from December
2005 to 2006. Inclusion criteria were: age 6–12 years;
and a clinical diagnosis of ADHD based on the relevant
DSM-IV diagnostic criteria and standardized clinical
assessments, as determined by experienced board-certifi-
cated child psychiatrists. Study approval was obtained
from the Institutional Review Board of Chang Gung
Memorial Hospital. Written informed consent was obtained
from the parents of each child and children following
an explanation of the study.
The diagnostic assessment of ADHD were performed by
two senior child psychiatrists, who administered structured
interviews using the Chinese-language version of the
Schedule for Affective Disorder and Schizophrenia for
School-Age Children [21], epidemiologic version (K-
SADS-E) [22]. This evaluation affirmed the clinical
diagnosis and excluded children who had co-morbid
pervasive developmental disorder, or a history of bipolar
disorder, psychosis, anxiety disorder, seizure disorder,
substance abuse or mental retardation. Other physical
and neurological examinations were performed by a
pediatrician and neurologist to rule out CNS or other
physical diseases. All ADHD children enrolled in this
study were drug-naïve at baseline. Treatment involved
administering 0.3-7 mg/kg/dose of MPH to all subjects,
which was within the range of the average daily dose in
Taiwan [23].
Measurements
Since executive function could be screened by the WISC
[9], we chose this psychometric measurement to evaluate
the neurocognitive performance of ADHD and healthy
children. After the initial screening, all the eligible children
were administered the WISC-III [24] by experienced child
psychologists. The ADHD-Rating scale [25] and Clinical
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simultaneously by an experienced child psychiatrist.
The WISC-III is a standardized intelligence test suitable
for children and adolescents aged 6–16 years. It contains
13 subtests, namely Information, Similarities, Arithmetic,
Vocabulary, Comprehension, Digit Span, Picture Comple-
tion, Coding, Picture Arrangement, Block Design, Object
Assembly, Symbol Search and Maze. VIQ, PIQ and full
IQ (FIQ), and their scores can be calculated based on
these subtests. The verbal comprehension index (VCI),
perceptual organization index (POI), freedom from
distractibility index (FDI), and processing speed index
(PSI) were also calculated from these subtests. The
WISC-III was used when the participants first enrolled
in the study. Repeated WISC-III tests were administered
for those who stayed in the study and received CNSTable 1 Characteristics of ADHD and normal children
ADHD (N = 171)
Mean ± SD or %
Age 8.7 ± 1.8
Male 81.9%
BMI 18.5 ± 3.7
ADHDRS_total 29.1 ± 8.2
ADHDRS_inattention 16.5 ± 4.2
ADHDRS_hyperactivity 12.8 ± 5.1
CGI –S 4.5 ± 0.8
WISC-III
Information 9.3 ± 2.9
Similarities 9.8 ± 3.3
Arithmetic 10.2 ± 3.1
Vocabulary 9.6 ± 3.1
Comprehension 9.7 ± 2.8
Picture completion 9.7 ± 3.0
Coding 9.1 ± 3.6
Picture arrangement 9.7 ± 2.9
Block design 10.5 ± 3.5
Object assembly 9.2 ± 3.1
Digit span 9.5 ± 3.0
Symbol search 10.5 ± 3.1
FIQ 97.6 ± 14.3
VIQ 98.2 ± 13.9
PIQ 98.2 ± 15.5
VCI 99.0 ± 13.6
POI 98.6 ± 14.4
FDI 98.7 ± 15.0
PSI 99.1 ± 15.5
1two sample t test, *: <0.05, **: <0.01 and ***: <0.001.
FIQ = full intelligence quotient, VIQ = verbal intelligence quotient, PIQ = performanc
organization index, FDI = freedom from distractibility index, PSI = processing speedstimulant treatment for one year. The second WISC-III
test was administered at least one year from the first
test. All participants were free from medication for at least
one week prior to the first and the second administration
of the WISC-III.
The ADHD-Rating scale is a structured interview
completed by the investigator based on information
from the parents and child. Each of the items has a 4-
point response scale, and each item explores one of the
18 criteria outlined in the DSM-IV to diagnose ADHD.
Higher scores indicate greater severity of ADHD. Initial
evaluation was scored when the ADHD children were
enrolled, and again at 6 months and one year into
treatment.
The CGI-S uses a 7-point scale with responses ranging
from 1 (normal) to 7 (the most severely ill patients). TheControl (N = 47) p value1
Mean ± SD or %
8.8 ± 2.1 0.654
51.1% <0.001 ***
18.8 ± 3.3 0.472
9.8 ± 6.5 <0.001 ***
6.7 ± 2.9 <0.001 ***
3.2 ± 4.0 <0.001 ***
1.0 ± 0.8 <0.001 ***
10.3 ± 2.7 0.182
12.4 ± 2.5 0.003 **
11.4 ± 1.8 0.121
11.3 ± 2.5 0.032 *
11.0 ± 2.4 0.087
10.9 ± 2.0 0.054
11.1 ± 3.6 0.033 *
11.7 ± 2.9 0.009
11.4 ± 2.3 0.158
9.9 ± 3.3 0.407
-
-
106.6 ± 9.5 0.014 *
107.0 ± 11.0 0.020 *
104.9 ± 9.6 0.103
107.8 ± 11.6 0.017 *
105.4 ± 10.7 0.078
e intelligence quotient, VCI = verbal comprehension index, POI = perceptual
index.
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and one year into the study, coinciding with the admin-
istration of the ADHD-Rating scale.Control group
To compare the differences between healthy children with-
out ADHD and children with ADHD in their performance
on the intelligence test, we recruited 47 age-matched
children (6–12 years) from surrounding schools in the
community by contacting the teachers. Inclusion criteria
included healthy children, as reported by the parents,
and the absence of ADHD symptoms. All children in the
control group were evaluated at the “child developmental
evaluation center” of the hospital, where physical, neuro-
logical and mental evaluations were performed by the
same specialists that saw the suspected ADHD children.
The exclusion criteria for the control group were the same
as those for the ADHD group.Table 2 Changes in ADHD symptoms and WISC-III scores of
ADHD children after MPH treatment for one year; N = 103
Mean ± SD P value1
ADHDRS_total −7.8 ± 6.7 <0.001 ***
ADHDRS_inattention −4.0 ± 3.8 <0.001 ***
ADHDRS_hyperactivity −3.8 ± 3.7 <0.001 ***
CGI –S −0.9 ± 0.8 <0.001 ***
WISC-III
Information 0.3 ± 1.6 0.103
Similarities 0.4 ± 2.0 0.075
Arithmetic 0.1 ± 1.9 0.504Data analysis
The variables of sample characteristics, scores on the
ADHD-Rating scale and CGI-S, and profiles of neurocog-
nitve performance evaluated via the WISC-III between the
healthy normal controls and the ADHD children were
compared using two sample t-tests and the chi-square test.
The changes in the ADHD-rating scale and CGI-S and in
performances on the WISC-III before and after MPH
treatment in the ADHD group were compared using the
paired t-test. The correlation between the changes in
the severity of ADHD symptoms and performance on
the WISC-III was analyzed via Pearson's correlation
coefficient. All tests were performed using SPSS 15.0,
with a 2-tailed significance level of 0.05.Vocabulary 0.3 ± 1.9 0.074
Comprehension −0.1 ± 1.6 0.434
Picture completion 0.8 ± 2.0 0.001 **
Coding 0.0 ± 2.7 0.911
Picture arrangement 0.8 ± 1.9 0.001 **Results
A total of 171 children with ADHD were included in our
study.Block design 0.2 ± 2.0 0.212
Object assembly 0.6 ± 2.1 0.012 *
Digit span 0.6 ± 1.9 0.043 *
Symbol search −0.6 ± 2.1 0.090
FIQ 2.9 ± 7.5 <0.001 ***
VIQ 1.6 ± 7.1 0.045 *
PIQ 3.9 ± 9.0 <0.001 ***
VCI 0.7 ± 6.1 0.312
POI 3.4 ± 7.3 <0.001 ***
FDI 1.0 ± 6.8 0.324
PSI 0.2 ± 9.4 0.874
1paired t test, *: <0.05, **: <0.01 and ***: <0.001.Differences in the neurocognitive performance of ADHD
and healthy normal children
Compared to the healthy children, the ADHD children
had significant differences in their scores on the
ADHD-Rating scale (Table 1), including inattention
(p < 0.001), hyperactivity (p < 0.001) and total (p < 0.001)
scores, and on the CGI-S (p < 0.001). Children with
ADHD also scored significantly worse than children
in the control group in FIQ (p < 0.05), VIQ (p < 0.05) and
several subtests of the WISC-III, including Similarities
(p < 0.01), Vocabulary (p < 0.05), Coding (p < 0.05) and
VCI (p < 0.05).Differences between ADHD children who received
stimulant drugs or not
Of the 171 ADHD children, 130 received MPH treatment.
The 41 ADHD children without MPH treatment were
younger (p < 0.01) and had less severity on the ADHD-
Rating scale, including hyperactivity (p < 0.01) and total
(p < 0.05) scores and on the CGI-S (p < 0.01), than those
under MPH treatment. However, there was no significant
difference in performance on the WISC-III between these
two groups.Difference within drug treatment groups between those
who received MPH beyond one year and those who were
lost to follow-up
In the MPH treatment group, 103 participants (79%)
continued in the study beyond one year. Children
who were lost to follow-up during the period of MPH
treatment had the same severity of ADHD symptoms,
but had better performance in FIQ (p < 0.05), VIQ
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Vocabulary (p < 0.001).Changes in neurocognitive function after long-term
MPH treatment
The 103 participants who stayed in the study beyond
one year were administered the ADHD-Rating scale and
the CGI-S at 6 months and one year. Psychometric
measures using the WISC-III were also completed for
the 103 participants again at the end of one year. All
subscores on the ADHD-Rating scale, including inattention
(p < 0.001), hyperactivity (p < 0.001) and total (p < 0.001),
and the CGI-S (p < 0.001) decreased significantly for ADHD
children after drug therapy. Significant increments in
the FIQ (p < 0.001), VIQ (p < 0.05) and PIQ (p < 0.001)
scores were also found in the MPH treatment group.
Among the subtests of the WISC-III, significant improve-
ments in performance were found in Picture Completion
(p < 0.01), Picture Arrangement (p < 0.01), Object Assembly
(p < 0.05), and Digit Span (p < 0.05). The POI (p < 0.001)Table 3 Pretreatment characteristics of two age groups of AD
6-8 years (N = 60)
Item Mean ± SD
ADHDRS_total 32.2 ± 8.0
ADHDRS_inattention 17.8 ± 5.1
ADHDRS_hyperactivity 14.4 ± 5.1
CGI –S 4.8 ± 0.8
WISC-III
Information 9.4 ± 2.4
Similarities 8.8 ± 3.4
Arithmetic 10.0 ± 3.2
Vocabulary 9.4 ± 3.5
Comprehension 9.8 ± 3.1
Picture completion 9.2 ± 2.9
Coding 9.2 ± 4.2
Picture arrangement 9.6 ± 2.8
Block design 10.5 ± 3.1
Object assembly 9.0 ± 2.7
Digit span 9.3 ± 2.6
Symbol search 11.0 ± 2.7
FIQ 96.4 ± 13.7
VIQ 97.1 ± 14.8
PIQ 97.8 ± 13.8
VCI 97.3 ± 13.8
POI 97.2 ± 12.6
FDI 98.5 ± 13.0
PSI 100.6 ± 16.7
1P value by 2 sample t-test; *: <0.05, **: <0.01.score also improved significantly after drug therapy
(Table 2).
Differences in the changes in neurocognitive function
after long-term MPH treatment among the ADHD children
with or without learning disorders
ADHD is often comorbid with learning disorders (LD),
which would influence performance on the WISC-III.
We subdivided the ADHD children with MPH treatment
into two groups. One group included 19 ADHD children
comorbid with LD and the other, ADHD children without
LD. However, we did not find a significant difference
between the two groups in the changes in ADHD
symptoms and in the WISC-III after MPH treatment.
Changes in neurocognitive function of ADHD children
with/without MPH treatment at the end of one year
We compared the differences between ADHD children
with/without MPH treatment for one year. The re-
sults showed that there was a significant increase in
FIQ (p < 0.001), VIQ (p < 0.05), PIQ (p < 0.001), PictureHD children
9-12 years (N = 70) P value1
Mean ± SD
27.9 ± 7.7 0.006 **
15.7 ± 3.3 0.007 **
12.6 ± 4.7 0.017 *
4.4 ± 0.9 0.007 **
9.3 ± 3.2 0.736
10.7 ± 3.1 0.002 **
10.3 ± 3.1 0.620
9.9 ± 2.5 0.433
9.7 ± 2.5 0.830
9.9 ± 3.2 0.211
8.9 ± 3.2 0.715
9.8 ± 3.1 0.673
10.8 ± 3.5 0.625
9.5 ± 3.2 0.414
9.8 ± 3.2 0.481
11.0 ± 2.4 0.989
99.0 ± 14.6 0.298
99.5 ± 13.4 0.369
98.9 ± 16.5 0.720
100.7 ± 13.2 0.181
100.2 ± 15.1 0.273
100.8 ± 15.8 0.504
99.9 ± 12.7 0.827
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Object assembly (p < 0.05), Digit span (p < 0.05) and POI
(p < 0.001) among the ADHD children who received MPH
treatment. However, there were no significant changes
in performance on the WISC-III among the ADHD
children not receiving MPH treatment. The sample size
of the ADHD children who received and did not receive
MPH treatment was 103 and 17, respectively.
Effect of MPH treatment on neurocognitive profiles in
different age groups
The ADHD children under MPH treatment were subdi-
vided into two age groups (6–8 years and 9–12 years).
The pre-treatment data of the 6–8 years age group were
found to be significantly higher in inattention (p < 0.01),
hyperactivity (p < 0.05), and total scores (p < 0.01) on the
ADHD-rating scale and CGI-S (p < 0.01), and signifi-
cantly lower on the Similarities subtest of the WISC-III
(p < 0.01) (Table 3). After one year of MPH treatment,
there were significant decrements in severity of ADHDTable 4 Changes in ADHD symptoms and WISC-III scores in th
6-8 years (N = 47)
Item Mean ± SD Sig.1
ADHDRS_total −7.0 ± 6.9 ***
ADHDRS_inattention −3.6 ± 4.0 ***
ADHDRS_hyperactivity −3.5 ± 3.6 ***
CGI –S −0.9 ± 0.7 ***
WISC-III
Information 0.4 ± 1.6
Similarities 1.1 ± 2.4 *
Arithmetic 0.1 ± 2.4
Vocabulary 0.5 ± 2.2
Comprehension 0.4 ± 1.7
Picture completion 0.7 ± 2.0 *
Coding −0.4 ± 3.0
Picture arrangement 0.5 ± 1.7
Block design 0.3 ± 2.1
Object assembly 1.2 ± 2.0 **
Digit span 0.7 ± 2.0
Symbol search −1.1 ± 2.8
FIQ 3.6 ± 7.0 **
VIQ 2.6 ± 8.5
PIQ 2.8 ± 8.8
VCI 2.2 ± 6.3
POI 3.4 ± 7.6 *
FDI 0.3 ± 6.6
PSI −1.3 ± 11.8
1by paired t-test; 2P value by 2 sample t-test.
*: <0.05, **: <0.01 and ***: <0.001.symptoms in both age groups, but without a statistically
significant difference in the range of improvement of
the two groups (Table 4). Significant improvements in
Similarities (p < 0.05), Picture Completion (p < 0.05), Object
Assembly (p < 0.01), FIQ (p < 0.01), and POI (p < 0.05)
were noted in the 6–8 years age group, and significant
improvements in Picture Completion (p < 0.05), Picture
Arrangement (p < 0.01), FIQ (p < 0.05), PIQ (p < 0.01) and
POI (p < 0.01) were noted in the 9–12 years age group.
However, the Comprehension subtest score decreased
significantly in the 9–12 years age group (p < 0.05) after
MPH treatment. When comparing the range of changes in
the WISC-III across these two age groups, more improve-
ment with statistical significance in the performances
of Similarities (p < 0.05), Comprehension (p < 0.05) and
Object Assembly (p < 0.05) were found in 6–8 years age
group after one year of MPH treatment. Based on these
results, more benefit from receiving MPH treatment
could be found in the younger age group (6–8 years)
than in the older age group (9–12 years).e two age groups after MPH treatment for one year
9-12 years (N = 56) P value2
Mean ± SD Sig.1
−8.4 ± 6.6 *** 0.351
−4.3 ± 3.5 *** 0.332
−4.0 ± 3.8 *** 0.526
−0.9 ± 1.0 *** 0.892
0.2 ± 1.6 0.695
−0.1 ± 1.4 0.013 *
0.1 ± 1.5 0.996
0.2 ± 1.6 0.545
−0.5 ± 1.5 * 0.015 *
0.9 ± 2.1 * 0.753
0.4 ± 2.3 0.093
1.0 ± 2.0 ** 0.254
0.2 ± 1.9 0.962
0.2 ± 2.1 0.048 *
0.5 ± 1.9 0.770
−0.2 ± 1.7 0.190
2.3 ± 7.8 * 0.367
0.8 ± 5.7 0.280
4.9 ± 9.2 ** 0.315
−0.5 ± 5.8 0.066
3.4 ± 7.2 ** 0.992
1.4 ± 7.0 0.616
1.1 ± 7.8 0.421
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different age groups of ADHD children with or without LD
When further subdividing the group of ADHD children
under MPH treatment comorbid with or without LD into
two age groups (6–8 years and 9–12 years), similar results
could be noted. More improvement with statistical sig-
nificance in the performances of Similarities (p < 0.01),
Comprehension (p < 0.05) and Object Assembly (p < 0.05)
was found in 6–8 years age group.Correlation between the changes in neurocognitive
profiles and severity of ADHD symptoms
No significant correlation was found between the changes
in performance on the WISC-III (including 13 subtests,
VCI, POI, FDI, PSI, FIQ, VIQ, and PIQ) and the severity
of ADHD symptoms as measured by the ADHD-Rating
scale and CGI-S (Table 5).Correlation between the changes in neurocognitive
profiles and baseline severity of ADHD symptoms
Similarly, there were no significant associations between
the changes of WISC-III and the baseline ADHD severity
and CGI scores in the MPH treatment group (Table 6).Table 5 Pearson correlation coefficients (R) between the chan
ADHD symptoms and CGI-S
WISC-III
ADHD RS_total ADHD RS_inatten
R P value R P v
Information 0.022 0.864 0.009 0
Similarities 0.177 0.169 0.133 0
Arithmetic 0.001 0.995 −0.091 0
Vocabulary 0.004 0.974 0.076 0
Comprehension −0.003 0.982 −0.023 0
Picture completion 0.229 0.076 0.168 0
Coding −0.016 0.883 −0.060 0
Picture arrangement 0.072 0.577 0.040 0
Block design 0.018 0.870 −0.014 0
Object assembly 0.104 0.419 0.094 0
Digit span −0.176 0.272 −0.164 0
Symbol search −0.032 0.853 −0.177 0
FIQ 0.081 0.459 0.032 0
VIQ 0.053 0.676 0.022 0
PIQ 0.104 0.407 0.065 0
VCI 0.122 0.356 0.135 0
POI 0.234 0.074 0.178 0
FDI −0.186 0.257 −0.300 0
PSI 0.035 0.841 0.009 0
ADHD RS: attention-deficit/hyperactivity disorder rating scale; CGI-S: clinical global iDiscussion
In this study, children with ADHD had lower VIQ and
FIQ than healthy children without ADHD. The findings
in this study showed that FIQ was approximately 9 points
lower in children with ADHD than in healthy children.
This is compatible with the results of a previous meta-
analytic review, which reported that ADHD groups
performed at an average of 9.15 FIQ points lower than
the control group [10]. We also found that children with
ADHD performed poorly on several subtests of the
WISC-III, including Similarities, Vocabulary, and Coding,
compared to healthy children. The finding that children
with ADHD perform poorly in Coding is consistent with
several studies [27-30]. However, there continues to be
incongruence in the profile of other WISC-III subtests for
children with ADHD. A previous study [9] revealed lower
scores in Picture Arrangement, Block Design, and Object
Assembly in ADHD groups. But their sample size of 26
control participants and 35 children with ADHD was
relatively small. Since their study had limited data and
various methodological differences from our study, com-
paring our results would result in inconsistencies.
The benefits to cognitive function after MPH treatment
were noted in many studies [31-34], but there is sparse
research and incongruent results in the area of the effectges in performance on the WISC-III and the changes of
tion ADHD RS _hyperactivity CGI-S
alue R P value R P value
.943 0.032 0.806 0.136 0.299
.303 0.193 0.129 0.152 0.241
.409 0.096 0.378 −0.024 0.826
.485 −0.071 0.510 0.020 0.856
.856 0.013 0.922 −0.224 0.083
.195 0.237 0.063 0.132 0.315
.583 0.026 0.814 0.074 0.503
.757 0.087 0.499 0.043 0.745
.897 0.048 0.656 0.008 0.944
.469 0.091 0.479 0.160 0.223
.305 −0.090 0.571 −0.123 0.448
.303 0.107 0.527 −0.120 0.494
.768 0.117 0.284 0.017 0.877
.864 0.078 0.531 0.083 0.512
.604 0.115 0.354 0.154 0.219
.310 0.090 0.492 0.010 0.942
.176 0.236 0.070 0.228 0.085
.063 −0.010 0.950 −0.106 0.528
.957 0.045 0.791 0.195 0.263
mpression-severity; R: Pearson’s correlation coefficients.
Table 6 Pearson correlation coefficients (R) between the changes in performance on the WISC-III and the baseline
ADHD symptoms and CGI-S
WISC-III
ADHDRS _total ADHDRS _inattention ADHDRS _hyperactivity CGI-S
R P value R P value R P value R P value
Information −0.040 0.744 0.047 0.701 −0.111 0.359 −0.138 0.254
Similarities −0.040 0.737 −0.015 0.900 −0.008 0.949 −0.016 0.893
Arithmetic −0.068 0.510 −0.039 0.703 −0.029 0.778 0.083 0.418
Vocabulary −0.116 0.255 −0.032 0.752 −0.129 0.205 −0.077 0.451
Comprehension −0.001 0.997 −0.213 0.072 0.084 0.481 0.223 0.060
Picture completion −0.157 0.195 −0.105 0.387 −0.016 0.893 −0.068 0.574
Coding −0.109 0.288 −0.119 0.248 0.026 0.802 −0.130 0.203
Picture arrangement −0.180 0.135 −0.107 0.379 −0.133 0.272 −0.114 0.346
Block design −0.099 0.330 −0.043 0.677 −0.133 0.193 −0.086 0.400
Object assembly −0.015 0.901 0.044 0.715 −0.024 0.841 −0.073 0.550
Digit span 0.146 0.329 0.222 0.134 0.047 0.754 0.138 0.354
Symbol search 0.131 0.409 0.143 0.367 0.075 0.638 0.205 0.192
FIQ −0.112 0.274 −0.080 0.435 −0.060 0.561 0.000 0.998
VIQ −0.156 0.184 −0.125 0.289 −0.138 0.242 −0.045 0.704
PIQ −0.177 0.128 −0.098 0.402 −0.089 0.447 −0.164 0.160
VCI −0.105 0.391 −0.091 0.456 −0.089 0.467 0.000 0.998
POI −0.175 0.151 −0.079 0.521 −0.114 0.349 −0.159 0.193
FDI −0.091 0.551 0.062 0.684 −0.152 0.319 0.030 0.843
PSI −0.105 0.507 −0.016 0.920 0.003 0.983 −0.127 0.422
ADHD RS: attention-deficit/hyperactivity disorder rating scale; CGI-S: clinical global impression-severity; R: Pearson’s correlation coefficients.
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the ADHD children's improvement on several WISC-III
subtests after drug treatment in this study was incompat-
ible with the results of another study that found a positive
effect of MPH on the verbal comprehension index [35].
Therefore, the potential influence of MPH on the per-
formance of ADHD children on the WISC-III, except for
the IQ scores, needs further research.
There are no recommendations regarding the optimal
period for ADHD drug treatment. According to the results
of this study, the degree of improvement in ADHD
symptom severity was not significantly different relative
to the patient's age on receiving MPH treatment. On
the other hand, significantly better performance in some
subtests and subscales of the WISC-III (such as Similar-
ities, Comprehension, and Object Assembly) was noted in
the 6–8 years age group. This suggests that it would be
best to start MPH treatment for ADHD at a younger age.
However, previous studies have not found that younger
age groups obtained more benefits in various aspects than
older age groups as a result of MPH treatment. Thus,
more research is needed to corroborate this finding and to
reach a conclusion.
It has been hypothesized that attention deficit in
ADHD children would substantially influence IQ [13],
so improving attention would secondarily improve IQscores. However, this hypothesis was not supported by
previous studies, which revealed no significant correlation
between the severity of ADHD symptoms and WISC-
III IQ scores [36,37]. In addition, the hypothesis that
improving attention would secondarily improve IQ scores
has also been refuted. Several studies found that improve-
ments in behavioral symptoms had no correlation with
changes in cognitive parameters [35,38,39]. This is also
consistent with our results that no association was found
between improvements in ADHD symptoms and changes
in the scores of the WISC-III subtests and subscales
(i.e., VCI, POI, FDI, PSI, FIQ, VIQ, and PIQ). It seems
that the better performance on intelligence tests after
MPH treatment did not result from lessening ADHD
symptoms. MPH may possibly produce a different benefit
and utilize another mechanism of improving performance
on the WISC-III, aside from ameliorating suboptimal
test-taking behavior in ADHD children. But MPH may
not actually improve construct of IQ as much as it just
improves accuracy on the test due to improved attention
should be kept in mind.
There are several limitations in this study. First, the
sample enrolled in the study did not include all patients
with ADHD, so the findings might not be applicable to
the entire population of ADHD patients. Second, the
sample size in the study was relatively small, particularly
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Symbol Search and Digit Span) were not administered to
the control group. Therefore, the statistical power in this
study was limited in its ability to detect the changes
from pre- to post-treatment and the differences between
ADHD and healthy children. Large-scale studies using
integrated psychometric measurements are needed. Third,
the majority of children with ADHD were male, so the in-
fluence of sex could not be ruled out. Fourth, this was not
a randomized controlled trial and whether to start MPH
treatment or not was based on clinical evaluation and
most importantly the opinions of the parents of the
ADHD children. Fifth, the interval between the 1st and 2nd
administration of the WISC-III was not long enough to
ignore the practical effect without controversy. Sixth, other
treatments (i.e., cognitive behavioral therapy, parental
training, attention training) associated with MPH treat-
ment were often performed in clinical practice, but the
interactions and their possible effect on the WISC-III
was not followed up in this study.
Although many limitations have been noted, a number
of strengths can also be found in this study. First, real-
world children with ADHD were sampled and given an
appropriate dose of MPH in line with clinical guidelines.
Second, the 1st and 2nd administration of the WISC-III was
given at least one year apart, thus reducing the possible
practical effect to a limited degree [24,40]. Although
the sample size of ADHD children with/without MPH
treatment was small in this study, the practical effect
could not totally explain the improvement in the WISC-
III after MPH treatment, because there were no significant
changes in the ADHD children who did not receive MPH
treatment after one year. Third, all participants were free
from medication for at least one week before performing
the WISC-III, which would reduce the direct influence
of medication on improving test-taking behavior. Thus,
the present study is valuable because of its strengths.Conclusion
According to the findings in this study, we suggest that
long-term MPH treatment may improve neurocognitive
profiles, which were shown in the performance of the
ADHD children on several subtests and in IQ scores of
the WISC-III. And the improvement had no correlation
with the decrement of ADHD symptoms and baseline
ADHD severity. Starting stimulant treatment at as
young an age as possible is advised due to the greater
benefits seen in the 6–8 years age group. But more
research using a controlled sample to replicate the findings
is needed.
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